Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of estrogen receptor positive breast cancer recurrence, but many women do not respond to therapy. Observational studies nested in clinical trial populations suggest that overexpression or nuclear localization of p21-activated kinas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta Oncol
Hauptverfasser: Ahern, Thomas P., Cronin-Fenton, Deirdre P., Lash, Timothy L., Sørensen, Henrik Toft, Ording, Anne Gulbech, Hamilton-Dutoit, Stephen J., Hellberg, Ylva
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943575/
https://ncbi.nlm.nih.gov/pubmed/27056567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2016.1150606
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge